Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

NCT05633667 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05633667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05633667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 16, 2023
Completion date
September 30, 2029
Enrollment
192 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic non-small-cell lung cancer, lung cancer, resectable non-small-cell lung cancer